{"id":23587,"date":"2025-04-13T17:40:01","date_gmt":"2025-04-13T17:40:01","guid":{"rendered":"https:\/\/researchchemicalstore.eu\/?post_type=product&p=23587"},"modified":"2025-10-03T07:27:28","modified_gmt":"2025-10-03T07:27:28","slug":"2-3-pastilles-fea-40-mg-120-mg","status":"publish","type":"product","link":"https:\/\/researchchemicalstore.eu\/fr\/produit\/2-3-pastilles-fea-40-mg-120-mg\/","title":{"rendered":"Granul\u00e9s 2\/3-FEA 40 MG\/120 MG"},"content":{"rendered":"

Granul\u00e9s 2\/3-FEA 40 mg \/ 120 mg \u2013 Description scientifique du produit<\/span><\/span><\/strong><\/h3>\n

Informations g\u00e9n\u00e9rales<\/span><\/span><\/strong><\/h4>\n

2\/3-FEA (2-fluoro\u00e9thylph\u00e9tamine\/3-fluoro\u00e9thylph\u00e9tamine)<\/span><\/span><\/strong> \u00a0est un\u00a0 <\/span><\/span>compos\u00e9 de recherche de la famille des d\u00e9riv\u00e9s de la fluoroamph\u00e9tamine<\/span><\/span><\/strong> , avec des propri\u00e9t\u00e9s stimulantes et empathog\u00e8nes potentielles. Ces granul\u00e9s contiennent un\u00a0 <\/span><\/span>Association pr\u00e9cis\u00e9ment dos\u00e9e de 40 mg de 2-FEA et de 120 mg de 3-FEA<\/span><\/span><\/strong> , optimis\u00e9 pour\u00a0 <\/span><\/span>\u00e9tudes pr\u00e9cliniques<\/span><\/span><\/strong> \u00a0ou interactions pharmacodynamiques.<\/span><\/span><\/p>\n

\n

Applications et domaines de recherche<\/span><\/span><\/strong><\/h3>\n

Gr\u00e2ce \u00e0 sa structure duale unique, la m\u00e9thode des \u00e9l\u00e9ments finis 2\/3 est \u00e9tudi\u00e9e pour\u00a0:<\/span><\/span><\/p>\n

    \n
  1. \n

    Recherche sur les neurotransmetteurs<\/span><\/span><\/strong> \u00a0\u2013 Effets sur la lib\u00e9ration de dopamine, de noradr\u00e9naline et de s\u00e9rotonine.<\/span><\/span><\/p>\n<\/li>\n

  2. \n

    Pharmacologie comportementale<\/span><\/span><\/strong> \u00a0\u2013 Influences sur l\u2019activit\u00e9 locomotrice et les syst\u00e8mes de r\u00e9compense chez les mod\u00e8les animaux.<\/span><\/span><\/p>\n<\/li>\n

  3. \n

    Effets stimulants<\/span><\/span><\/strong> \u00a0\u2013 \u00c9tudes comparatives avec les amph\u00e9tamines classiques.<\/span><\/span><\/p>\n<\/li>\n

  4. \n

    \u00c9tudes d'affinit\u00e9 des r\u00e9cepteurs<\/span><\/span><\/strong> \u00a0\u2013 \u00c9tude de la s\u00e9lectivit\u00e9 des transporteurs de monoamines.<\/span><\/span><\/p>\n<\/li>\n<\/ol>\n

    \u26a0\u00a0Ne pas utiliser chez l'homme \u2013 R\u00e9serv\u00e9 aux tests in vitro et aux tests sur animaux contr\u00f4l\u00e9s.<\/span><\/span><\/strong><\/p>\n

    \n

    Posologie et administration<\/span><\/span><\/strong><\/h3>\n

    Lignes directrices pr\u00e9cliniques\u00a0:<\/span><\/span><\/strong><\/h4>\n
      \n
    • \n

      Port\u00e9e active faible\u00a0:<\/span><\/span><\/strong> \u00a00,5 \u00e0 2 mg\/kg (pour des effets subtils)<\/span><\/span><\/p>\n<\/li>\n

    • \n

      Port\u00e9e mod\u00e9r\u00e9e\u00a0:<\/span><\/span><\/strong> \u00a02-5 mg\/kg (effets comportementaux clairs)<\/span><\/span><\/p>\n<\/li>\n

    • \n

      Haute gamme :<\/span><\/span><\/strong> \u00a05 \u00e0 10 mg\/kg (uniquement pour les \u00e9tudes de toxicit\u00e9 aigu\u00eb)<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

      Solubilit\u00e9:<\/span><\/span><\/strong><\/h4>\n
        \n
      • \n

        Librement soluble dans\u00a0 <\/span><\/span>solution saline physiologique<\/span><\/span><\/strong> \u00a0(pour injection)<\/span><\/span><\/p>\n<\/li>\n

      • \n

        Peu soluble dans\u00a0 <\/span><\/span>DMSO<\/span><\/span><\/strong> \u00a0(pour les travaux in vitro)<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

        Voies d'administration :<\/span><\/span><\/strong><\/h4>\n
          \n
        • \n

          Voie orale (mod\u00e8les animaux)<\/span><\/span><\/p>\n<\/li>\n

        • \n

          Intrap\u00e9riton\u00e9ale (pour une absorption plus rapide)<\/span><\/span><\/p>\n<\/li>\n

        • \n

          Essais de transporteurs in vitro<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

          \n

          Aspects et risques li\u00e9s \u00e0 la s\u00e9curit\u00e9<\/span><\/span><\/strong><\/h3>\n

          Risques aigus\u00a0:<\/span><\/span><\/strong><\/h4>\n
            \n
          • \n

            Stress cardiovasculaire<\/span><\/span><\/strong> \u00a0(augmentation du rythme cardiaque\/de la pression art\u00e9rielle)<\/span><\/span><\/p>\n<\/li>\n

          • \n

            \u00a0dose \u00e9lev\u00e9e <\/span>hyperthermie<\/span><\/strong><\/span><\/p>\n<\/li>\n

          • \n

            syndrome s\u00e9rotoninergique<\/span><\/span><\/strong> \u00a0en association avec des inhibiteurs de la MAO<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

            Risques chroniques\u00a0:<\/span><\/span><\/strong><\/h4>\n
              \n
            • \n

              Neurotoxicit\u00e9<\/span><\/span><\/strong> \u00a0(\u00e0 doses \u00e9lev\u00e9es sur le long terme)<\/span><\/span><\/p>\n<\/li>\n

            • \n

              \u00c9puisement dopaminergique<\/span><\/span><\/strong><\/p>\n<\/li>\n

            • \n

              sensibilisation comportementale<\/span><\/span><\/strong><\/p>\n<\/li>\n<\/ul>\n

              \n

              Analyses en laboratoire et contr\u00f4le qualit\u00e9<\/span><\/span><\/strong><\/h3>\n

              Sp\u00e9cifications analytiques\u00a0:<\/span><\/span><\/strong><\/h4>\n
                \n
              • \n

                Confirmation par HPLC-MS<\/span><\/span><\/strong> \u00a0de composition<\/span><\/span><\/p>\n<\/li>\n

              • \n

                Rapport 1:3 (2-FEA:3-FEA)<\/span><\/span><\/strong> \u00a0avec une variance <5%<\/span><\/span><\/p>\n<\/li>\n

              • \n

                Aucune impuret\u00e9 isom\u00e8re d\u00e9tectable<\/span><\/span><\/strong><\/p>\n<\/li>\n

              • \n

                Puret\u00e9 microbiologique :<\/span><\/span><\/strong> \u00a0<100 UFC\/g<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                Donn\u00e9es de stabilit\u00e9 :<\/span><\/span><\/strong><\/h4>\n
                  \n
                • \n

                  Dur\u00e9e de conservation :<\/span><\/span><\/strong> \u00a024 mois \u00e0 4\u00b0C<\/span><\/span><\/p>\n<\/li>\n

                • \n

                  Photosensibilit\u00e9:<\/span><\/span><\/strong> \u00a0Conserver dans un emballage ambr\u00e9<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                  \n

                  Protocoles de recherche recommand\u00e9s<\/span><\/span><\/strong><\/h3>\n
                    \n
                  1. \n

                    \u00c9tudes de microdialyse<\/span><\/span><\/strong><\/p>\n

                      \n
                    • \n

                      Surveillance en temps r\u00e9el de la dopamine extracellulaire dans le noyau accumbens<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n

                    • \n

                      Pr\u00e9f\u00e9rence de lieu conditionn\u00e9e<\/span><\/span><\/strong><\/p>\n

                        \n
                      • \n

                        \u00c9valuation du potentiel de r\u00e9compense<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n

                      • \n

                        \u00c9tudes sur la thermor\u00e9gulation<\/span><\/span><\/strong><\/p>\n

                          \n
                        • \n

                          Effets sur la temp\u00e9rature corporelle<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n

                        • \n

                          \u00c9lectrophysiologie<\/span><\/span><\/strong><\/p>\n

                            \n
                          • \n

                            Analyse des sch\u00e9mas d'activation des neurones dopaminergiques<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n

                            \n

                            Questions fr\u00e9quemment pos\u00e9es<\/span><\/span><\/strong><\/h3>\n

                            Q1 : Quelle est la principale diff\u00e9rence entre l'analyse par \u00e9l\u00e9ments finis \u00e0 2 \u00e9l\u00e9ments et l'analyse par \u00e9l\u00e9ments finis \u00e0 3 \u00e9l\u00e9ments ?<\/span><\/span><\/strong>
                            \n A : L'analyse par \u00e9l\u00e9ments finis \u00e0 deux facteurs (2-FEA) pr\u00e9sente une plus grande efficacit\u00e9\u00a0 <\/span><\/span>s\u00e9lectivit\u00e9 dopaminergique<\/span><\/span><\/strong> , tandis que l'analyse par \u00e9l\u00e9ments finis \u00e0 3 niveaux (3-FEA) est plus robuste\u00a0 <\/span><\/span>effets s\u00e9rotoninergiques<\/span><\/span><\/strong> \u00a0.<\/span><\/span><\/p>\n

                            Q2 : Comment cette combinaison se compare-t-elle au 3-FMA ?<\/span><\/span><\/strong>
                            \n A : La combinaison 2\/3-FEA poss\u00e8de une\u00a0 <\/span><\/span>profil d'effet plus mod\u00e9r\u00e9<\/span><\/span><\/strong> \u00a0avec un potentiel de neurotoxicit\u00e9 plus faible.<\/span><\/span><\/p>\n

                            Q3 : Existe-t-il un risque de formation d'isom\u00e8res ?<\/span><\/span><\/strong>
                            \n A : Nos donn\u00e9es analytiques montrent que\u00a0 <\/span><\/span>aucun isom\u00e8re ind\u00e9sirable<\/span><\/span><\/strong> \u00a0se forment lorsqu'elles sont stock\u00e9es correctement.<\/span><\/span><\/p>\n

                            \n

                            Note juridique :<\/span><\/span><\/strong>
                            \n Ce produit rel\u00e8ve de la cat\u00e9gorie\u00a0 <\/span><\/span>Loi sur l'opium<\/span><\/span><\/strong> \u00a0aux Pays-Bas et est\u00a0 <\/span><\/span>destin\u00e9 exclusivement \u00e0 la recherche scientifique l\u00e9gale<\/span><\/span><\/strong> \u00a0avec les permis n\u00e9cessaires.<\/span><\/span><\/p>\n

                            Conditions de stockage :<\/span><\/span><\/strong><\/p>\n

                              \n
                            • \n

                              Temp\u00e9rature : 2-8\u00b0C<\/span><\/span><\/p>\n<\/li>\n

                            • \n

                              Prot\u00e9g\u00e9 de l'humidit\u00e9 et de la lumi\u00e8re<\/span><\/span><\/p>\n<\/li>\n

                            • \n

                              Conserver \u00e0 l'\u00e9cart des aliments<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                              ","protected":false},"excerpt":{"rendered":"

                              Remplac\u00e9 par des granul\u00e9s Newphoria 2\/3-FEA >><\/span><\/span><\/span><\/span><\/strong><\/span><\/p>","protected":false},"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[322,333,324],"product_tag":[326],"class_list":{"0":"post-23587","1":"product","2":"type-product","3":"status-publish","5":"product_cat-bijna-verboden","6":"product_cat-gefluoreerden","7":"product_cat-pellets-for-pellet","8":"product_tag-nl","10":"first","11":"instock","12":"taxable","13":"shipping-taxable","14":"purchasable","15":"product-type-variable"},"_links":{"self":[{"href":"https:\/\/researchchemicalstore.eu\/fr\/wp-json\/wp\/v2\/product\/23587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/researchchemicalstore.eu\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/researchchemicalstore.eu\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/fr\/wp-json\/wp\/v2\/comments?post=23587"}],"version-history":[{"count":5,"href":"https:\/\/researchchemicalstore.eu\/fr\/wp-json\/wp\/v2\/product\/23587\/revisions"}],"predecessor-version":[{"id":28068,"href":"https:\/\/researchchemicalstore.eu\/fr\/wp-json\/wp\/v2\/product\/23587\/revisions\/28068"}],"wp:attachment":[{"href":"https:\/\/researchchemicalstore.eu\/fr\/wp-json\/wp\/v2\/media?parent=23587"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/fr\/wp-json\/wp\/v2\/product_brand?post=23587"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/fr\/wp-json\/wp\/v2\/product_cat?post=23587"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/fr\/wp-json\/wp\/v2\/product_tag?post=23587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}